The University of Osaka · 의학
아츠나리 카와시마 교수의 연구실은 신장세포암(신세포암)을 중심으로 면역세포, 특히 T세포의 기능과 표적치료 반응성을 탐구하고 있습니다. CD8 및 CD4 T세포의 여포성 상태와 면역관문 분자(예: PD-1, TIM-3)의 발현 패tern이 종양의 진행성과 예후에 미치는 영향을 유전체 분석을 통해 규명하고 있으며, 특히 면역세포의 기능 이상이 암의 악성도와 연관됨을 밝혀내고 있습니다. 또한, 혈액 생화학적 지표(예: 저나트륨혈증, CRP)가 표적치료 반응과 생존에 미치는 영향을 임상적 예측 인자로 평가하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Although further study is needed, ERCC1 expression level may predict the efficacy of CRT for MIBC.
It is important to evaluate the clinical importance of both CD8 T cells and CD4 T cells expression simultaneously because they have crucial networks in tumour targeting immune responses. In 97 RCC patients, RNA sequencing and gene set enrichment analysis of both CD8 and CD4 T cells based on the expression levels of PD-1 and TIM-3 implied that the populations of PD-1+TIM-3+ CD8 T cells and PD-1lowTIM-3 + CD4 T cells were characterized as exhausted CD8 T cells and regulatory CD4 T cells, respectiv
Hyponatremia (<138 mEq/L), neutrophilia and high C-reactive protein levels seem to represent significant predictive factors for cancer-specific survival in metastatic renal cell carcinoma patients treated with molecular targeted therapy as first line therapy. Furthermore, hyponatremia might be significantly associated with chronic inflammation and tumor aggressiveness.
Sorafenib was effective in Japanese patients with advanced renal cell carcinoma in general clinical practice and was tolerated although most patients required dose reduction or interruption of therapy. Future studies should establish new strategies for treatment without sacrificing both efficacy and patient quality of life.
The expression of CD4+CD8+ T cells was significantly up-regulated in RCC patients and correlated significantly with prognostic importance in surgically treated RCC patients.
